Stocks Health care RCUS
NYSE · Health careArcus Biosciences, Inc. (RCUS)
Arcus Biosciences, Inc. brought in $117M of revenue over the twelve months to June 30, 2026, down 55.3% from a year earlier. It posted a net loss of $460M. In fiscal 2025 capital spending exceeded operating cash flow by $484M. At June 30, 2026 it held $150M in cash against $101M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
What Arcus Biosciences, Inc. does
Arcus Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker RCUS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $247M | -$353M | -$3.29 | -$484M |
| 2024 | $258M | -$283M | -$3.14 | -$176M |
| 2023 | $117M | -$307M | -$4.15 | -$330M |
| 2022 | $112M | -$267M | -$3.71 | $432M |
| 2021 | $383M | $53M | $0.71 | -$282M |
| 2020 | $78M | -$123M | -$2.24 | $108M |
Latest SEC filings
What Arcus Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026
- August 5, 2026
- June 12, 2026
- May 5, 2026Quarterly report 10-Q · period to March 31, 2026
- May 5, 2026
- April 21, 2026
- April 21, 2026Additional proxy material DEFA14A
- April 21, 2026Proxy statement DEF 14A
- April 20, 2026Other event 8-K
- March 26, 2026Passive stake changed SCHEDULE 13G/A
Questions about RCUS
What does Arcus Biosciences, Inc. do?
Arcus Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker RCUS.
Is Arcus Biosciences, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $460M on revenue of $117M.
How much revenue does Arcus Biosciences, Inc. make?
Over the twelve months to June 30, 2026 Arcus Biosciences, Inc. reported revenue of $117M. That is 55.3% less than a year earlier.
When did Arcus Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from August 24, 2026.
Similar companies
Follow RCUS
Get an email when Arcus Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow RCUS: get an email when it filesWhere the numbers come from
Financial figures are the values Arcus Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.